| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma (NCT06160206) | Academic and Community Cancer Research United | 2024-10-02 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy (NCT06238648) | Academic and Community Cancer Research United | 2024-01-31 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT05910801) | Academic and Community Cancer Research United | 2024-01-04 |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study (NCT05356897) | Academic and Community Cancer Research United | 2023-10-31 |
| Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer (NCT05194293) | Academic and Community Cancer Research United | 2023-07-01 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab (NCT05199285) | Academic and Community Cancer Research United | 2023-01-19 |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma (NCT04756401) | Academic and Community Cancer Research United | 2022-12-08 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer (NCT05168163) | Academic and Community Cancer Research United | 2022-05-27 |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy (NCT05246670) | Academic and Community Cancer Research United | 2022-05-16 |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (NCT04626791) | Academic and Community Cancer Research United | 2021-08-03 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760) | Academic and Community Cancer Research United | 2021-06-16 |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (NCT04088188) | Academic and Community Cancer Research United | 2021-01-25 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) (NCT04665115) | Academic and Community Cancer Research United | 2020-11-23 |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation (NCT04390243) | Academic and Community Cancer Research United | 2020-11-16 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (NCT04351230) | Academic and Community Cancer Research United | 2020-11-11 |
| Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations (NCT04096417) | Academic and Community Cancer Research United | 2020-08-31 |
| Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (NCT03841565) | Academic and Community Cancer Research United | 2020-08-07 |
| Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations (NCT04042831) | Academic and Community Cancer Research United | 2020-06-24 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456) | Academic and Community Cancer Research United | 2020-04-24 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial (NCT03765736) | Academic and Community Cancer Research United | 2020-04-20 |
| Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer (NCT04117945) | Academic and Community Cancer Research United | 2020-03-03 |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery (NCT04197687) | Academic and Community Cancer Research United | 2020-02-20 |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer (NCT03981614) | Academic and Community Cancer Research United | 2019-10-29 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087) | Academic and Community Cancer Research United | 2018-11-02 |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT03334409) | Academic and Community Cancer Research United | 2018-02-16 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (NCT02973997) | Academic and Community Cancer Research United | 2018-02-07 |
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (NCT03233347) | Academic and Community Cancer Research United | 2017-10-13 |